CVS Health Corp (CVS)

Sep 28, 2026

Verizon's stock has cooled recently despite a strong year, but the company boasts a 6% dividend yield and is developing two new growth catalysts: the Frontier fiber network and early AI infrastructure revenue. These new drivers, along with a reasonable valuation at 9x forward earnings, could reshape Verizon's long-term growth trajectory and offer significant upside despite challenges like debt and a softer average revenue per account.

Sep 27, 2026

This article compares the dividend investment merits of Polaris (PII) and Hasbro (HAS) for retirement portfolios. While Polaris offers a higher yield and a 31-year streak of dividend raises, the analysis suggests Hasbro, despite freezing its dividend, is a safer bet due to stronger cash flow coverage and business health. The author advises that Hasbro is better for retirees needing consistent income, while Polaris suits younger investors willing to accept more volatility for higher yield potential.

Sep 26, 2026

Microsoft Corporation (MSFT) stock closed at $516.17, up 3.7%, approaching its all-time high, with a 46% rally since June. While daily charts confirm a strong bullish trend with price above all major moving averages, momentum oscillators and Bollinger Bands suggest potential short-term overextension and a subtle bearish divergence on the MACD. Key resistance levels are identified, and fundamental catalysts like Copilot overhaul and AI investments support the long-term outlook, though a near-term cooling-off period is plausible.

Sep 26, 2026

CVS Health Corporation stock surged 4.8% on September 25th, reclaiming the 200-day EMA and daily pivot after eight consecutive losing sessions. Despite this rally, the daily chart indicates the stock remains in a broader downtrend, with price still below key moving averages and a negative MACD histogram. While hourly momentum has turned bullish, signaling a short-term rebound, intraday charts show signs of exhaustion, suggesting the rally might be due for a pause.

Sep 25, 2026

CVS Health Corporation's stock has risen by 5.09% following strategic healthcare expansion initiatives, including Aetna's expansion of oncology prior authorization bundles for Medicaid cancers, with a Medicare and commercial rollout planned for 2027. The company's financial overview shows strong cash generation and manageable balance sheet leverage, despite thin margins. Analysts project double-digit upside for CVS, with a 12-month target of $110.

Sep 25, 2026

CVS Health Corporation's stock rose by 4.8% following positive sentiment regarding its healthcare services growth prospects, particularly Aetna's expansion of its bundled oncology prior authorization program. Analysts have increased price targets for CVS, signaling potential upside, while the company continues to invest in community-based care initiatives. The article highlights strong cash generation and an undemanding valuation, suggesting a bullish trend for the stock.

Sep 25, 2026

CVS Health's Aetna division is projected to reach an adjusted operating income of $5.37 billion in 2026, which merely returns it to 2021 levels after a significant drop in 2024. The article highlights a concern that AI tools used by providers are identifying more billable diagnoses without a corresponding increase in treatment, potentially driving up healthcare costs. This trend, already noted by other insurers, could impact Aetna's medical cost trends and leaves CVS with a thin cushion given its 2027 EPS consensus is only slightly above management's stated floor.

Sep 24, 2026

CVS Health's 2027 outlook is clouded by uncertainties surrounding its 340B business, which management expects to be a drag on its pharmacy services. Despite a recent stock decline and unquantified risks, CVS management raised its 2026 earnings outlook and still aims for mid-teens EPS growth through 2028. Investors should monitor the fiscal Q3 2026 report to see if Health Services profit can absorb the 340B impact and maintain the company's growth trajectory.

Sep 24, 2026

UnitedHealth (UNH) is facing significant margin pressure in its commercial segment due to issues like arbitration abuse under the No Surprises Act and increased provider coding intensity, which a Blue Cross Blue Shield Association study linked to AI tools used by providers, costing insurers $942 million industry-wide. Management has pushed back commercial margin recovery targets to beyond 2027. UnitedHealth is responding by leveraging its Optum Insight segment, which provides AI-driven coding accuracy and prior authorization tools, to counteract these billing challenges, with its operating margin recently swinging from a loss to a record 25.4%.

Sep 24, 2026

QRG Capital Management Inc. significantly increased its stake in CVS Health Corporation, purchasing an additional 87,757 shares in the second quarter to reach a total of 185,242 shares valued at $19.2 million. This move is part of a broader trend of institutional investors and hedge funds owning a large percentage of CVS shares. Analysts maintain a favorable outlook on CVS Health, with a "Moderate Buy" consensus and an average price target of $107.24, despite a recent dip in stock price.

Sep 24, 2026

Envestnet Asset Management Inc. significantly increased its stake in CVS Health Corporation, adding 1.55 million shares to reach a total of 3.48 million shares valued at $359.5 million. This comes as CVS Health reported strong second-quarter earnings, exceeding analyst expectations with adjusted earnings of $2.58 per share and revenue of $106.1 billion. Analysts maintain a "Moderate Buy" rating for CVS, with a consensus price target of $107.24, and the company also offers a quarterly dividend.

Sep 23, 2026

UnitedHealth Group (UNH) stock has significantly risen since March 2026, following the company's previously announced strategy to improve margins by exiting less managed plans and narrowing Medicare Advantage networks. The company's adjusted earnings per share have increased, and it raised its full-year 2026 adjusted earnings outlook, indicating the success of its planned adjustments and cost reductions. However, the commercial book's margin recovery is still projected to extend beyond 2027, suggesting ongoing areas for improvement.

Sep 23, 2026

CVS Health Corp. (CVS) shares fell 1.42% to $85.86 on Wednesday, marking its seventh consecutive day of losses. This occurred during a general market downturn, with the S&P 500 Index (SPX) dropping 0.75% and the Dow Jones Industrial Average (DJIA) falling 0.68%. Despite the daily losses, the article title suggests CVS outperformed its competitors.

Sep 23, 2026

Florida Attorney General James Uthmeier has filed a lawsuit against three major drug manufacturers—Eli Lilly, Novo Nordisk, and Sanofi—along with three large pharmacy benefit managers (PBMs)—CVS Caremark, Express Scripts, and Optum Rx. The lawsuit alleges that these companies colluded to inflate insulin prices, with drugmakers setting high prices and then paying significant rebates to PBMs for formulary placement, thereby ensuring mutual profit from the rising costs. This legal action mirrors a previous lawsuit by the Federal Trade Commission against PBMs and group purchasing organizations regarding insulin pricing practices.

Sep 23, 2026

CVS Pharmacy has agreed to a $20.5 million class action settlement regarding allegations that it shared user data from its digital properties with third parties without authorization. Customers who visited CVS websites or the app before July 27, 2026, may be eligible for a payout of up to $10 with proof of membership or up to $5 without documentation. The deadline to file a claim is November 16, and a court hearing for approval is set for December 1.

Sep 23, 2026

Investors are currently evaluating Caterpillar (NYSE:CAT) based on equipment demand and dealer inventories, raising questions about whether this attention reflects a lasting change in execution or a temporary market reaction. The article emphasizes that future company updates need to clearly link strategy with observable business outcomes to strengthen the investment case. While Caterpillar's NYSE Composite listing provides market context, the company must demonstrate concrete operational improvements and disciplined capital allocation to earn a re-rating, rather than relying solely on sector narratives.

Sep 23, 2026

Coca-Cola's market story is being re-evaluated based on global beverage demand and pricing discipline. Investors are looking for concrete evidence from the company to support this renewed interest, rather than relying solely on market sentiment. Future company commentary and operating disclosures will be crucial in determining if the current market attention reflects sustainable execution.

Sep 22, 2026

State Street Corp significantly increased its holdings in CVS Health Corporation by 26.3% in the second quarter, acquiring an additional 15.6 million shares. This brings State Street's total ownership to 5.86% of CVS Health. Other institutional investors also made substantial moves, with BlackRock Inc. purchasing a new stake valued at over $12.7 billion and Wellington Management Group LLP increasing its holdings by 49.8%.

Sep 22, 2026

Nick Riehl, Principal Accounting Officer of Moelis & Co (NYSE:MC), recently acquired five tranches of dividend equivalent Restricted Stock Units (RSUs) on September 17, 2026. These acquisitions were made at a $0 conversion price and are linked to unvested underlying RSUs from various past grant programs, with their vesting aligned to the original grants. Following these transactions, Riehl's holdings in different RSU programs have increased, as detailed in the SEC Form 4 filing on September 21, 2026.

Sep 22, 2026

Halliburton (NYSE:HAL) is worth watching due to service demand influenced by crude oil volatility and its impact on drilling budgets. The broader market is characterized by selective trading, emphasizing business quality, operating consistency, and sector-specific demand amidst fluctuating interest rates, energy prices, and global trade discussions. The article highlights the importance of company-specific execution and demand signals to assess Halliburton's performance within the nuanced oil and gas sector.

Sep 22, 2026

SLB (NYSE:SLB) is currently in focus due to oilfield activity amidst easing crude prices and moderating supply concerns. The article emphasizes that the broader market remains selective, prioritizing business quality and consistent operations, making company-specific execution crucial for oil and gas stocks. Future clarity on SLB's performance will depend on upcoming company communications regarding demand, operations, and sector conditions.

Sep 22, 2026

The article discusses AiRWA (NASDAQ: YYAI) as a penny stock to watch, emphasizing its relevance due to small technology visibility within the artificial intelligence sector. It highlights that the current market is selective, balancing high interest rates, energy prices, global trade, and AI, which necessitates focusing on company-specific execution and operational resilience for penny stocks. The piece stresses the importance of distinguishing between price action and verified business evidence, urging investors to monitor sector fundamentals interacting with the broader American market.

Sep 22, 2026

AbbVie (NYSE:ABBV) is a relevant stock to watch today as defensive healthcare demand supports the sector. The market is selective, focusing on business quality and execution amid varied macroeconomic factors like interest rates, energy prices, and technology interest. The company's business model durability and customer demand signals will be key in understanding its performance within the current market environment.

Sep 22, 2026

CVS Health Corporation (NYSE: CVS) shows a potential upside of 30.89% based on analyst targets, trading at $88.84, near its 52-week low. The company boasts strong financial metrics including $113.62 billion market cap, 7.10% revenue growth, and an attractive dividend yield of 2.99%, supported by 24 buy ratings. Its diversified healthcare segments and strategic focus position it for future growth and make it a compelling investment for those seeking exposure to the healthcare sector.

Sep 22, 2026

Haleon is targeting users of GLP-1 weight-loss drugs like Wegovy and Zepbound to drive growth in the U.S. market. By strategically placing products that address common side effects of these drugs in stores like CVS, Haleon has seen a significant increase in per-store sales. While this strategy offers a promising new revenue stream and helps strengthen brands like Advil, its overall impact on Haleon's group-level revenue growth remains to be fully seen.

Sep 21, 2026

Dollar Tree (NASDAQ:DLTR) is being observed today due to a focus on value retail traffic following a previous softer session. The company's performance is currently influenced by interest rates, energy markets, trade policies, and internal operating execution. Upcoming disclosures from Dollar Tree are expected to provide clarity on these trends and how they impact the company's outlook in the broader retail landscape.

Sep 21, 2026

CVS and other health care companies are seeking to subpoena private emails and communications of Tennessee lawmakers and lobbyists. This action is part of an escalating battle over a Tennessee law that prohibits single entities from owning insurers, pharmacies, and pharmacy benefit managers. The companies aim to gather information related to the discussions surrounding this controversial law.

Sep 21, 2026

Genius Sports (NYSE:GENI) operates in the sports technology sector, providing official sports data, digital content, technology, and advertising services. The company has demonstrated strong revenue growth, with its latest quarterly revenue reaching approximately $195.5 million, though it continues to report net losses. Genius Sports' business model integrates official sports data with digital media, advertising, and fan engagement, serving a broad international customer base across sports organizations, broadcasters, and sportsbooks.

Sep 20, 2026

Wall Street Zen upgraded CVS Health (NYSE:CVS) to a "strong-buy" rating, contributing to an overall "moderate buy" consensus from analysts with an average price target of $107.24. This upgrade follows CVS's robust quarterly results, which saw adjusted EPS of $2.58 against a $1.87 consensus and $106.1 billion in revenue, marking a 7.3% year-over-year increase. Institutional investors hold a significant portion of CVS shares, with major acquisitions by BlackRock, Wellington Management, and Bank of America in the second quarter.

Sep 19, 2026

Cardinal Health (NYSE:CAH) projects a 13-15% adjusted EPS growth for fiscal year 2027, primarily driven by operating income growth across its business segments, and reiterates a longer-term EPS growth target of 12-14%. Specialty services, including oncology, urology, and autoimmune care, are anticipated to be a key growth engine, with BioPharma Solutions aiming for $1 billion in revenue by fiscal 2028. The company also plans $1 billion in share repurchases and expects contributions from at-home solutions and recent acquisitions, while managing the recovery of its medical-products division.

Sep 18, 2026

A Philadelphia jury has found Kenvue, formerly Johnson & Johnson Consumer Inc., not liable in lawsuits alleging its aerosol sunscreen caused cancer deaths. The lawsuits were brought by the estates of two women who died from cancer.

Sep 18, 2026

This article reviews the Q2 earnings performance of several health insurance providers, highlighting CVS Health (NYSE:CVS) as a strong performer despite a subsequent stock price drop. It details the financial results for CVS Health, Centene, Progyny, Oscar Health, and Clover Health, noting revenue beats and guidance updates. The piece also briefly touches on broader market concerns like AI's impact and geopolitical events affecting investor sentiment.

Sep 18, 2026

A new survey reveals that one-third of privately insured adults under 65 are burdened by medical debt, with nearly half owing $2,000 or more. This debt often stems from hospital services and even routine care, leading to significant stress and financial strain, causing many to delay necessary healthcare or cut back on basic necessities. The findings highlight a critical failure in the healthcare system, with respondents blaming insurance companies and the broader system, and favoring solutions like interest-free payment plans and financial assistance.

Sep 18, 2026

Nykredit A S has acquired 2.03 million shares of CVS Health Corporation, valued at approximately $209.8 million, making CVS its 22nd largest position. Institutional investors and hedge funds now collectively own 80.66% of CVS. Despite a recent stock decline, analysts maintain a "Moderate Buy" rating with an average price target of $107.24, and the company offers a $2.66 annualized dividend yielding about 2.9%.

Sep 17, 2026

CVS Health's Aetna health insurance unit announced it will simplify the prior authorization process for cancer treatments starting in 2027. Instead of multiple approvals for various components of care, providers will submit a single preapproval based on documentation showing the patient is receiving cancer treatment. This change aims to reduce administrative burden for healthcare providers and will be rolled out across private, Medicare Advantage, and some Medicaid plans.

Sep 16, 2026

CVS Health is currently trading at a significant discount compared to both Wall Street analyst targets and its internal valuation model, suggesting it may be an undervalued stock. While analysts are already bullish, the company's strong Q2 earnings, raised EPS guidance, and Aetna's margin recovery support an even more optimistic outlook. However, risks such as potential PBM re-regulation and drug pricing rules could impact future performance.

Sep 16, 2026

Haleon, the maker of Advil and TUMS, has seen a boost in U.S. sales by strategically targeting consumers using GLP-1 weight-loss drugs. The company is collaborating with retailers like CVS Pharmacy to place its products, which alleviate common side-effects of these drugs, in dedicated "GLP-1 destination sets" and regular aisles. This dual placement strategy has resulted in a 24% sales lift per store for Haleon, capitalizing on the growing number of Americans using weight-loss medications.

Sep 16, 2026

CVS Health (NYSE: CVS) is currently a prominent topic in value stock discussions due to broader market themes like rising oil costs, firming Treasury yields, and an uncertain Federal Reserve outlook. The article emphasizes that while external factors influence daily trading, CVS Health's operational execution, customer demand, and response to competitive conditions remain critical to its market position and investor interest. The company's ongoing relevance stems from its intersection with current economic narratives, including technology demand, energy sensitivity, and health services.

Sep 15, 2026

CVS Health's Health Services business is demonstrating strong growth, driven by favorable pharmacy drug mix, brand inflation, and improved Health Care Delivery, notably through Oak Street Health. The company's Caremark division is securing significant new sales and achieving substantial client savings with its biosimilar strategy. Competitors like UnitedHealth's Optum and Elevance Health's Carelon are also expanding their healthcare service offerings through integrated care models and value-based solutions.

Sep 15, 2026

CVS Health awarded a grant to Windy City Harvest during a community event at Grace Manor in Chicago's North Lawndale neighborhood. This event, supported by Aetna Better Health of Illinois and Oak Street Health, focused on providing health, wellness, education, and economic opportunities to residents. It highlighted CVS Health's ongoing commitment to supporting the Grace Manor affordable housing community and fostering community well-being through partnerships and resource provision.

Sep 15, 2026

Alcoa (AA) is gaining market attention due to a renewed focus on industrial demand and energy costs affecting aluminum exposure. The article highlights Alcoa's distinct position in aluminum production and processing as crucial to understanding its current relevance. It emphasizes that while broad market trends like the NYSE Composite provide context, Alcoa's story is driven by its specific operational details, customer demand, and management execution.

Sep 15, 2026

Bank of America Corp DE significantly increased its stake in CVS Health Corporation, buying an additional 13.8 million shares and now owning 1.81% of the company worth nearly $2.4 billion. Other institutional investors also adjusted their positions in CVS Health, which recently reported strong quarterly earnings and declared a quarterly dividend. Analysts maintain a "Moderate Buy" consensus rating for CVS Health, with an average target price of $107.24.

Sep 14, 2026

Phoebe A. Wood, a director at Invesco Ltd. (NYSE:IVZ), sold 3,000 common shares at $32.44 each on September 11, 2026. This transaction was an open market sale, leaving her with 107,111.157 shares directly held. The disclosure was filed with the SEC, confirming no derivative securities transactions.

Sep 14, 2026

Louis Navellier has provided updated Stock Grader recommendations for 93 blue-chip stocks, based on institutional buying pressure and fundamental health. Key upgrades include Intel (INTC) from Strong to Very Strong, while CVS Health (CVS) was downgraded from Very Strong to Strong. The article details comprehensive lists of upgrades and downgrades across various rating categories.

Sep 14, 2026

Aurinia Pharmaceuticals' Chief Legal Officer, Stephen P. Robertson, sold 11,939 shares of the company's stock at $15.95 per share on September 10, 2026. This transaction reduced his stake by approximately 2.0%, leaving him with 588,848 shares. The sale details were filed under code S.

Sep 14, 2026

Anthony P J Smurfit, CEO of Smurfit Westrock plc, acquired 486 ordinary shares and 910 Restricted Stock Units (RSUs) on September 10, 2026, as dividend equivalents. These acquisitions were made at no cost, linked to a quarterly dividend of $0.4523 per share. Post-transaction, Smurfit directly beneficially owns 1,728,994 ordinary shares, including various tranches of RSUs set to vest in the future.

Sep 14, 2026

This article features Chelsey Shaw, a registered nurse with Coram CVS Specialty Infusion Services, who has dedicated 13 years to providing home infusion therapies for patients with rare and genetic diseases. Her professional perspective was deepened when her own adopted son required home health care, giving her firsthand experience as a recipient of the services she provides. Chelsey emphasizes the importance of home-based nursing, highlighting the sense of safety and belonging it offers to patients.

Sep 14, 2026

Currie Harriss T, CFO of AdaptHealth Corp. (NASDAQ:AHCO), was granted 141,372 shares on September 9, 2026, establishing a new insider position. This transaction, filed under SEC transaction code A, represents 100% of Harriss’s total AdaptHealth shareholding. Following this award, Harriss now holds 141,372 shares in the company.